PTPN11 and neoplasm: Further study indicated that the anti-tumor activity of MRTX849 was significantly improved when combined with upstream (EGFR and SHP2) inhibitors and downstream (mTOR and cyclin-dependent kinase 4/6) (CDK4/6) inhibitors [67].